D.E. Shaw & Co’s Eucrates Biomedical Acquisition Corp. Ordinary Shares EUCR Stock Holding History

D.E. Shaw & Co’s Portfolio EUCR Stock Details EUCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-666,171	Closed	-$6.68M	–	5310
2022 Q3	$6.68M	Hold	666,171	–	–	0.01%	1759
2022 Q2	$6.59M	Buy	666,171 +162,000	+32%	+$1.6M	0.01%	1798
2022 Q1	$4.97M	Buy	504,171 +25,502	+5%	+$250K	﹤0.01%	2316
2021 Q4	$4.67M	Buy	478,669 +302,988	+172%	+$2.97M	﹤0.01%	2447
2021 Q3	$1.72M	Buy	175,681 +54,646	+45%	+$533K	﹤0.01%	3176
2021 Q2	$1.19M	Buy	+121,035	New	+$1.19M	﹤0.01%	3399

Other funds holding EUCR

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

SIA

SkyView Investment Advisors Shrewsbury, New Jersey $743M AUM 17.91% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

D.E. Shaw & Co's EUCR Position: Q4 2022 in Review

D.E. Shaw & Co sold out of Eucrates Biomedical Acquisition Corp. Ordinary Shares (EUCR) in Q4 2022, closing a stake of 666,171 shares — an estimated $6.68M sold.

D.E. Shaw & Co first reported a position in EUCR in Q2 2021 and held it in 6 quarters. The position peaked at $6.68M in Q3 2022. 5 funds tracked by Wall St. Rank hold EUCR as of Q4 2022.

D.E. Shaw & Co reported no remaining Eucrates Biomedical Acquisition Corp. Ordinary Shares position as of Q4 2022 after selling out during the quarter.
D.E. Shaw & Co sold 666,171 Eucrates Biomedical Acquisition Corp. Ordinary Shares shares in Q4 2022, an estimated $6.68M.
D.E. Shaw & Co first reported a position in Eucrates Biomedical Acquisition Corp. Ordinary Shares in Q2 2021 and held it in 6 quarters.
D.E. Shaw & Co's Eucrates Biomedical Acquisition Corp. Ordinary Shares position peaked at $6.68M in Q3 2022.
5 funds tracked by Wall St. Rank held Eucrates Biomedical Acquisition Corp. Ordinary Shares as of Q4 2022.

Based on D.E. Shaw & Co's 13F filing for Q4 2022, filed 14 Feb 2023.